Leaders in Pharmaceutical Business Intelligence (LPBI) Group

LIVE 4:00 pm – 4:50 pm 4/25/2016 Winning Portfolio Strategy @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston

2016 World Medical Innovation Forum: CANCER, April 25-27, 2016,

Partners HealthCare, Boston, at the Westin Hotel, Boston

ANNOUNCEMENT

Leaders in Pharmaceutical Business intelligence (LPBI) Group

will cover in Real Time using Social Media this Event on

CANCER Innovations

Aviva Lev-Ari, PhD, RN, Founder LPBI Group & Editor-in-Chief

http://pharmaceuticalintelligence.com

Streaming LIVE @Westin in Boston

worldmedicalinnovation.org

• allocation drug across indications vs per cancer type
• $1Billion vs $3Billion — TRUE cost to develop a drug
• innovation starts Where?
• Support of internal investigators
• relations with Academia is critical – at MGH it is very important Academia and Clinical
• Me toos vs Blockbusters drugs?? – question from the audience
• Mergers among Big Pharma – question from the audience
• BioSimilars are they innovation??? – question from the audience
• What will slow down innovations

• Optiva lung carcinoma – large population and renal – small population
• immune based cancers
• $100Billions goes to Drug development need to add NIH Budget
• Exciting Science in 2016 like never before
• set an innovation fund to find academics to solve problems
• collaboration with the Community: Optiva a case in point
• No interest in BioSimilars
• Combination – will be the winner
• worry about DISRUPTION – from Academia or Biotech

• Immuno-oncology works on large populations trends will be to go to smaller populations
• best biology the biggest benefit to patients
• why cost of clinical research is going up
• can we do drug development for less
• Value in the marketplace in the very early stage
• culture is critical How to create the culture to innovate at big Pharma
• External innovations and Internal innovation very important
• Mergers are spenders since they require fusion
• worries me: novel, novel regimes and combination – Crisis can emerge

• direct cost of a successful drug with accelerated schedule of clinical trials
• cost of failure
• approval $300,000 from that point bringing it to the market
• stochastic process for innovations and everywhere
• more people work on same drug — better product
• Mergers was about bringing a new product and market
• Generic drugs will free investments for R&D and innovations – good for the industry as a whole
• Precision medicine – is based on technology
• Best in disease – if found, obsolescence is increasing

• allocation to integrate immune oncology differentiation and integration
• $1 – $2Billion
• Cancer Metabolism – WILL BE THE BIGGEST INNOVATION
• Incubator of new ideas, deep experience – CAR-T innovation from UPenn academic link
• in cancer Me too is important, though Novartis stay away from me too
• it is differentiation and integration
• R&D merger is there is synergy to speed up innovations
• GSK and Novartis was a swap to leverage expertise in respective areas
• Novartis portfolio was accelerated – it took one year, now there are advantages
• Pace of innovation is fast and energizes – Prioritization – will left out some patients

• From Millenium to Takeda
• Oncology  will drive to smaller population types of diseases
• $1.6Billion to develop a Cancer drug
• what is value of BioTech – outside is brought in
• co-mechanisms: myeloma
• no me toos at Takeda — only what will differentiation us
• BioGenerics can be smart
• breakthrough are very fast, divergence across the Globe, programming streaming is harder to do